Internal Medicine, Endocrinology, Diabetes, & Metabolism · Chesterfield, MO
NPI
1255365581
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
222 S Woods Mill Rd
Chesterfield, MO, 63017
Phone (314) 469-6224
Groups this clinician bills Medicare through
Medicare paid, 2024
$541K
12,913 services
Medicare patients, 2024
879
Average age 75
Drug cost, 2024
$6.8M
11,392 prescriptions
Company payments, 2025
$11K
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ralph Oiknine was code 99490 (chronic, principal, and transitional care management), 2,167 times for 391 patients. In total Ralph Oiknine billed 12,913 services in 29 codes, and Medicare paid $541K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-09-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99490 Chronic, Principal, and Transitional Care Management | Office | 2,167 | 391 | $47.07 | $102K |
| 99214 Office E&M - Established | Office | 2,035 | 749 | $83.71 | $170K |
| 95251 Test - Miscellaneous | Office | 1,661 | 273 | $24.83 | $41K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 1,594 | 386 | $35.35 | $56K |
| 99454 E&M - Miscellaneous | Office | 1,328 | 197 | $33.88 | $45K |
| 83021 Blood Count | Office | 1,006 | 569 | $17.58 | $18K |
| 84443 Clinical Chemistry | Office | 549 | 438 | $16.37 | $8,989 |
| 84439 Clinical Chemistry | Office | 547 | 436 | $8.79 | $4,810 |
| 84480 Clinical Chemistry | Office | 547 | 436 | $13.83 | $7,563 |
| 82607 Clinical Chemistry | Office | 327 | 319 | $14.73 | $4,818 |
| 82306 Clinical Chemistry | Office | 321 | 315 | $28.92 | $9,283 |
| 80061 Clinical Chemistry | Office | 296 | 285 | $13.08 | $3,872 |
| 36415 Venipuncture Blood Collection | Office | 179 | 157 | $7.80 | $1,396 |
| 76536 Ultrasound - Nonspecific | Office | 115 | 114 | $76.02 | $8,743 |
| 99457 E&M - Miscellaneous | Office | 54 | 32 | $36.75 | $1,985 |
By year: 2022 $263K for 7,181 services; 2023 $324K for 8,755 services; 2024 $541K for 12,913 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83021 Blood Count | 1,006 | 569 | $17.58 | $18K |
| 84443 Clinical Chemistry | 549 | 438 | $16.37 | $8,989 |
| 84480 Clinical Chemistry | 547 | 436 | $13.83 | $7,563 |
| 84439 Clinical Chemistry | 547 | 436 | $8.79 | $4,810 |
| 82607 Clinical Chemistry | 327 | 319 | $14.73 | $4,818 |
| 82306 Clinical Chemistry | 321 | 315 | $28.92 | $9,283 |
| 80061 Clinical Chemistry | 296 | 285 | $13.08 | $3,872 |
| 36415 Venipuncture Blood Collection | 179 | 157 | $7.80 | $1,396 |
Medicare prescription drug claims, 2024
In 2024, the drug Ralph Oiknine prescribed most often to Medicare patients was Ozempic (Semaglutide), with 1,073 prescriptions and refills. In total Ralph Oiknine wrote 11,392 Medicare prescriptions that cost $6.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 1,073 | 1,967 | 243 | $1.9M |
| Levothyroxine Sodium Generic | 857 | 2,320 | 213 | $7,962 |
| Metformin Hcl Er Metformin Hcl | 776 | 2,207 | 219 | $8,420 |
| Metformin Hcl Generic | 619 | 1,769 | 176 | $4,453 |
| Farxiga Dapagliflozin Propanediol | 523 | 1,144 | 130 | $621K |
| Mounjaro Tirzepatide | 509 | 716 | 106 | $757K |
| Trulicity Dulaglutide | 445 | 757 | 99 | $730K |
| Synthroid Levothyroxine Sodium | 372 | 936 | 99 | $37K |
| Jardiance Empagliflozin | 369 | 837 | 101 | $481K |
| Atorvastatin Calcium Generic | 357 | 1,022 | 105 | $2,333 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 318 | 818 | 103 | $46K |
| Tresiba Flextouch U-100 Insulin Degludec | 271 | 850 | 100 | $172K |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 269 | 516 | 63 | $365K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 235 | 605 | 95 | $23K |
| Humalog Insulin Lispro | 205 | 517 | 68 | $74K |
Brand drugs: 6,073 claims; generic drugs: 4,302 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ralph Oiknine $11K ($11K in general payments such as food, travel and fees) from 24 companies. The largest payer was Abbvie Inc. with $3,963.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 5 | $3,963 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 8 | $3,921 |
| Lilly USA, LLC LLY | 7 | $973 |
| Senseonics, Incorporated SENS | 1 | $400 |
| Novo Nordisk Inc NVO | 13 | $341 |
| Sequel Med Tech, LLC | 14 | $319 |
| Ascensia Diabetes Care Us Inc. | 2 | $127 |
| Tandem Diabetes Care, Inc. TNDM | 1 | $115 |
| Sanofi-Aventis U.S. LLC SNY | 2 | $62.21 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $50.33 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.